Thursday, 4 November 2010

Oxford biomedics

A new trial may be started for a drug called TroVax which has been used in prostate Cancer and is to, hopefully, be put on trial for Mesothelioma in the first quarter of 2011. 

Trovax is a therapeutic vaccine that stimulates the immue system to destroy cancerous cells expressing the 5T4 tumour antigen.  The product is based on an attenuated modified vaccinia virus engineered to deliver the 5T4 antigen.

Lets hope something comes from this for us meso sufferers

No comments:

Post a Comment